Pasar al contenido principal

Resultados relacionados

Resultados totales (Incluyendo duplicados): 2
Encontrada(s) 1 página(s)

DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Metformin overcomes metabolic reprogramming-induced resistance of skin squamous cell carcinoma to photodynamic therapy

  • Mascaraque-Checa, Marta
  • Gallego-Rentero, María
  • Nicolás-Morala, Jimena
  • Portillo-Esnaola, Mikel
  • Cuezva, José M.
  • González, Salvador
  • Gilaberte, Yolanda
  • Juarranz, Ángeles
Objective: Cancer metabolic reprogramming promotes resistance to therapies. In this study, we addressed the role of the Warburg effect in the resistance to photodynamic therapy (PDT) in skin squamous cell carcinoma (sSCC). Furthermore, we assessed the effect of metformin treatment, an antidiabetic type II drug that modulates metabolism, as adjuvant to PDT. Methods: For that, we have used two human SCC cell lines: SCC13 and A431, called parental (P) and from these cell lines we have generated the corresponding PDT resistant cells (10GT). Results: Here, we show that 10GT cells induced metabolic reprogramming to an enhanced aerobic glycolysis and reduced activity of oxidative phosphorylation, which could influence the response to PDT. This result was also confirmed in P and 10GT SCC13 tumors developed in mice. The treatment with metformin caused a reduction in aerobic glycolysis and an increase in oxidative phosphorylation in 10GT sSCC cells. Finally, the combination of metformin with PDT improved the cytotoxic effects on P and 10GT cells. The combined treatment induced an increase in the protoporphyrin IX production, in the reactive oxygen species generation and in the AMPK expression and produced the inhibition of AKT/mTOR pathway. The greater efficacy of combined treatments was also seen in vivo, in xenografts of P and 10GT SCC13 cells. Conclusions: Altogether, our results reveal that PDT resistance implies, at least partially, a metabolic reprogramming towards aerobic glycolysis that is prevented by metformin treatment. Therefore, metformin may constitute an excellent adjuvant for PDT in sSCC., This research was supported by Spanish grants from Instituto de Salud Carlos III MINECO and Feder Funds (FIS PI15/00974; PI18/00858 and PI18/00708) and Ministerio de Ciencia, Innovación y Universidades (PID2019-108674RB-100).
Zaguán. Repositorio Digital de la Universidad de Zaragoza
Publicación Otros (Other)

Photodynamic therapy (PDT) in oncology

  • Juarranz, Á.
  • Gilaberte, Y.
  • González, S.
The issue is focused on Photodynamic Therapy (PDT), which is a minimally invasive therapeutic modality approved for treatment of several types of cancer and non-oncological disorders. PDT is being used in dermatology for the treatment of non-melanoma skin cancers (basal cell carcinoma, BCC, and Bowen disease, BD) and precancerous lesions (actinic keratosis, AKs), among other tumors such as: head and neck cancer and bladder and gynaecological neoplasms. PDT can also be used for cancer diagnosis by means of theragnosis (a term arising from the combination of diagnostic tests and therapy), a promising technique based on targeted fluorescent imaging and PDT. Photofrin and aminolevulinic acid and its ester derivatives are the main compounds used in clinical trials although newer photosensitizers (PSs) and delivery tools are being evaluated. This Special Issue on Cancers includes original articles on photochemical mechanisms, new PSs and delivery tools, cellular and tissue targets, cellular response (cell death or survival), vascular damage and immune response. We hope all the articles published in this Special Issue can help to improve this therapeutic cancer modality.